Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety-Reference-Cited by-同舟云学术

Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety

Published:2013-01-31 Issue:8 Volume:27 Page:1707-1714
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Badros A Z,Vij R,Martin T,Zonder J A,Kunkel L,Wang Z,Lee S,Wong A F,Niesvizky R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201329.pdf

Reference29 articles.

1. Bladé J, Fernandez-Llama P, Bosch F, Montoliu J, Lens XM, Montoto S et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch Intern Med 1998; 158: 1889–1893.

2. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Nordic Myeloma Study Group. Eur J Haematol 2000; 65: 175–181.

3. Sengul S, Li M, Batuman V . Myeloma kidney: toward its prevention--with new insights from in vitro and in vivo models of renal injury. J Nephrol 2009; 22: 17–28.

4. Knudsen LM, Hippe E, Hjorth M, Holmberg E, Westin J . Renal function in newly diagnosed multiple myeloma--a demographic study of 1353 patients. The Nordic Myeloma Study Group. Eur J Haematol 1994; 53: 207–212.

5. Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21–33.

Cited by 132 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Free Light Chain Kinetics Is Predictive of Renal Response in Myeloma Patients With Renal Impairment—An ALLG Trial of Carfilzomib-Dexamethasone Therapy in Frontline and Relapse;Clinical Lymphoma Myeloma and Leukemia;2024-08

2. Risk factors associated with overall survival in patients with multiple myeloma following carfilzomib treatment: A retrospective study from a large claims database in Japan;Cancer Medicine;2023-09-26

3. Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma;Blood Reviews;2023-09

4. Proteomic Alteration in the Progression of Multiple Myeloma: A Comprehensive Review;Diagnostics;2023-07-10

5. Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group;The Lancet Oncology;2023-07